title: Respiratory syncytial virus: a prioritized or neglected target?
authors.affiliation: Department of Antimicrobial Research, Tibotec-Virco Virology BVBA, Johnson & Johnson, Turnhoutseweg 30, B-2340 Beerse, Belgium. droymans@its.jnj.com
authors.forename: Dirk
authors.initials: D
authors.lastname: Roymans
authors.forename: Anil
authors.initials: A
authors.lastname: Koul
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008958:Models, Molecular; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects*; D054852:Small Molecule Libraries / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014764:Viral Proteins / Q000378:metabolism; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D054852:Small Molecule Libraries; D014764:Viral Proteins